Navigation Links
Immunotherapy Does Not Prolong Life When Skin Cancer Spreads

The addition of immunotherapy to chemotherapy for malignant skin cancer that has spread does not improve survival rates, researchers have //found, and patients have more serious side effects, such as anemia, when the two treatments are combined.

Malignant melanoma develops when cancer grows in the cells responsible for skin color, and is one of the most aggressive forms of skin cancer. Having unusual moles, exposure to sunlight and being fair-skinned are thought to place people at higher risk.

The use of oral or injected chemotherapy drugs to kill melanoma cancer cells can be effective if the cancer is diagnosed early, but once it has spread — metastasized — it is almost always fatal.

According to the National Cancer Institute, each year about 53,600 people in the United States are diagnosed with melanoma and 7,400 die from it. The incidence of melanoma has risen an alarming 3 percent a year since 1981, according to the Centers for Disease Control and Prevention.

Researchers have hoped that a combination of immunotherapy — treatment that bolsters or stimulates patients’ immune systems — and chemotherapy might be an option for people with malignant melanoma.

Authors led by Andre Sasse, M.D., at the research center Onco-Evidencias in Sao Paolo, Brazil, reviewed 18 studies of 2,625 patients who were treated with either chemotherapy alone or a combination of chemo- and immunotherapy.

“No difference was seen in survival rate and toxic effects were increased” when immunotherapy was added to chemotherapy, the researchers write.

The review appears in the current issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.

The review examined tw o kinds of immunotherapy combined with chemotherapy, interferon and interleukin-2. Of the 11 studies that reported on side effects from chemoimmunotherapy, eight showed blood disorders and flu-like symptoms resulting from the combined treatment. In four studies that used interleukin-2 without interferon, patients had more blood side effects after treatment.

Jedd Wolchok, M.D., an oncologist at Memorial Sloan-Kettering Cancer Center, said that it is difficult to tease out which of the two immunotherapy agents might be responsible for the side effects to patients’ blood.

“Both immunotherapies have considerable side effects,” Wolchok said. “Interleukin-2 is likely more difficult since it can lower blood pressure and cause fluid to build up in the body. These side effects are a consequence of what these immune hormones were originally designed to do — for example, interferon is a natural antiviral agent, so the fact that it causes flu-like symptoms very commonly is not a surprise.”

Sasse said, “The interleukin is more toxic and needs hospitalization for its administration. It is also known to promote more systemic reactions than interferon. But the adverse effects of either drug are dose dependent.”

Wolchok said, “This area should definitely continue to be investigated. My hypothesis is that chemotherapy may be used to modulate and potentiate newer immunotherapy drugs.”

Sasse, however, said, “There are some controversies about the use of chemotherapy in advanced melanoma — the chemotherapy does not save lives and additionally, there is doubt that it prolongs the survival of these patients.”

“My opinion is that there are enough studies in this subject and therefore, no need of new trials,” Sasse added. “At the moment, the focus should be given to the development of new therapeutic approaches to melanoma.” He cited advances in molecular biology and the carcinogenesis of melanoma as possible avenues f or new treatment in the future.
SRM
'"/>




Related medicine news :

1. Immunotherapy For Cancer Treatment
2. Passive Immunotherapy Could Prevent Avian Flu from Affecting Humans
3. Immunotherapy Does Not Prolong Life When Skin Cancer Spreads
4. Prolonged survival not assured by psychological therapies for cancer patients
5. Better Diet Even Late in Life May Prolong It
6. Novel Treatment Found To Prolong Survival Of Liver Cancer Patients
7. Prolonged Use Of Contraceptive Pill Dianette May Cause Depression
8. Woman Elects For Mastectomy: Prolonged Wait For Genetic Results
9. Effect of Prolonged Stay in Space Studied Using Fruit Flies
10. Physical Activity of any kind to Prolong Life
11. AIDS Sufferers Turn to British Doctor to Prolong their Survival
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... CA (PRWEB) , ... June 27, 2016 , ... ... College District , the only authorized OSHA Training Institute Education Center headquartered in ... by protecting their workers from extreme heat at their worksites. Employers with ...
(Date:6/27/2016)... ... 2016 , ... "FCPX editors can now reveal their media with growing colorful ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings the ... can now reveal the media of their split screens with growing colorful panels. , ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... to the network of the Tennessee Counseling Association, adding exclusive benefits and promotional ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... payment industry today announced its strategic partnership with Connance, a healthcare industry ... The two companies’ proven, proprietary technology combine to provide health systems, hospitals ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... cutting edge technology to revolutionize the emergency ambulance transport experience for the millions ... aware of how Uber has disrupted the taxi industry through the use of ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 26, 2016 One of Australia,s ... formation of a new biotechnology company, Noxopharm Limited [ABN 50 608 ... IPO and to list on the ASX. Noxopharm is ... to enter a Phase 1 clinical study later this year. ... one of the biggest problems facing cancer patients - the ability ...
(Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
(Date:6/26/2016)... 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) ... measures required to build a strong and stable market ... listed on the OTC Markets-pink current trading platform. ... "We are seeing an anomaly in market trading activities ... by the Company, but shareholders and market players as ...
Breaking Medicine Technology: